drugset / Trial / NCT01035502
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment with cytarabine (ara-C). In addition, the correlation between hENT1 (human equilibrative nucleoside transporter 1) and overall survival will be studied.
Timeline
- Start
- 2009-12
- Primary completion
- 2013-05
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacytarabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Elacytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Background | Idarubicin | Small molecule | 12 mg/m2 | Intravenous |